RJA
PPBT

Raymond James & Associates’s Purple Biotech PPBT Stock Holding History

Raymond James & Associates’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$4.07K – 4079
2024
Q2 		$4.07K Hold
50
– – ﹤0.01% 3946
2024
Q1 		$6.7K Sell
50
-5
-9% -$717 ﹤0.01% 3907
2023
Q4 		$8.58K Hold
55
– – ﹤0.01% 3803
2023
Q3 		$13.1K Hold
55
– – ﹤0.01% 3752
2023
Q2 		$15.3K Hold
55
– – ﹤0.01% 3787
2023
Q1 		$19.7K Buy
+55
New +$20.6K ﹤0.01% 3801
2017
Q1 		– Sell
-9
Closed -$57K – 3374
2016
Q4 		$57K Buy
+9
New +$62.7K ﹤0.01% 3088

Other funds holding PPBT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

Raymond James & Associates's PPBT Position: Q3 2024 in Review

Raymond James & Associates sold out of Purple Biotech (PPBT) in Q3 2024, closing a stake of 50 shares — an estimated $4.07K sold.

Raymond James & Associates first reported a position in PPBT in Q4 2016 and held it in 7 quarters. The position peaked at $57K in Q4 2016. 10 funds tracked by Wall St. Rank hold PPBT as of Q3 2024.

  • Raymond James & Associates reported no remaining Purple Biotech position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 50 Purple Biotech shares in Q3 2024, an estimated $4.07K.
  • Raymond James & Associates first reported a position in Purple Biotech in Q4 2016 and held it in 7 quarters.
  • Raymond James & Associates's Purple Biotech position peaked at $57K in Q4 2016.
  • 10 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.